Equities analysts predict that Integra Lifesciences Holdings Corp (NASDAQ:IART) will post sales of $351.57 million for the current quarter, according to Zacks. Six analysts have made estimates for Integra Lifesciences’ earnings. The lowest sales estimate is $345.90 million and the highest is $354.49 million. Integra Lifesciences reported sales of $255.66 million in the same quarter last year, which indicates a positive year over year growth rate of 37.5%. The company is scheduled to announce its next quarterly earnings report on Thursday, February 22nd.

On average, analysts expect that Integra Lifesciences will report full year sales of $351.57 million for the current year. For the next financial year, analysts forecast that the business will post sales of $1.47 billion per share, with estimates ranging from $1.46 billion to $1.48 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for Integra Lifesciences.

Integra Lifesciences (NASDAQ:IART) last announced its earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.47 by ($0.02). Integra Lifesciences had a return on equity of 16.35% and a net margin of 4.52%. The company had revenue of $278.83 million for the quarter, compared to analyst estimates of $286.00 million. During the same quarter in the previous year, the company posted $0.93 earnings per share. Integra Lifesciences’s revenue for the quarter was up 11.4% on a year-over-year basis.

A number of equities analysts have recently issued reports on the stock. Barclays reiterated an “equal weight” rating and set a $53.00 target price (up from $47.00) on shares of Integra Lifesciences in a research report on Tuesday, September 12th. Jefferies Group reiterated a “buy” rating on shares of Integra Lifesciences in a research report on Sunday, September 10th. Oppenheimer reiterated a “buy” rating and set a $60.00 target price on shares of Integra Lifesciences in a research report on Monday, September 18th. Finally, Zacks Investment Research lowered shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a report on Monday, October 9th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $53.64.

In other Integra Lifesciences news, VP Richard D. Gorelick sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total value of $70,785.00. Following the completion of the sale, the vice president now owns 21,665 shares of the company’s stock, valued at $1,022,371.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Barbara B. Hill bought 10,768 shares of the stock in a transaction on Tuesday, October 31st. The stock was purchased at an average cost of $46.66 per share, with a total value of $502,434.88. Following the purchase, the director now directly owns 55,540 shares of the company’s stock, valued at approximately $2,591,496.40. The disclosure for this purchase can be found here. Corporate insiders own 21.50% of the company’s stock.

A number of large investors have recently modified their holdings of IART. Acrospire Investment Management LLC increased its stake in Integra Lifesciences by 280.0% in the second quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after purchasing an additional 1,400 shares in the last quarter. Riverhead Capital Management LLC increased its stake in Integra Lifesciences by 49.9% in the second quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after purchasing an additional 799 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Integra Lifesciences by 8.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock valued at $150,000 after purchasing an additional 218 shares in the last quarter. Whittier Trust Co. bought a new stake in Integra Lifesciences in the third quarter valued at approximately $169,000. Finally, San Francisco Sentry Investment Group CA bought a new stake in Integra Lifesciences in the second quarter valued at approximately $174,000. 87.58% of the stock is owned by hedge funds and other institutional investors.

Shares of Integra Lifesciences (NASDAQ:IART) traded up $0.08 during mid-day trading on Friday, hitting $47.17. 312,700 shares of the stock were exchanged, compared to its average volume of 502,700. Integra Lifesciences has a 12 month low of $40.51 and a 12 month high of $56.42. The firm has a market capitalization of $3,695.50, a price-to-earnings ratio of 77.33, a price-to-earnings-growth ratio of 1.56 and a beta of 0.65. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39.

TRADEMARK VIOLATION NOTICE: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/05/brokerages-expect-integra-lifesciences-holdings-corp-iart-will-post-quarterly-sales-of-351-57-million.html.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Get a free copy of the Zacks research report on Integra Lifesciences (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.